Sezary Syndrome (Sezary Erythroderma)

Subscribe to Selected New Research on Sezary Syndrome

102 relevant articles (6 outcomes, 10 trials/studies) found for this Disease

Description: A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).

Also Known As:

Sezary Erythroderma; Syndrome, Sezary; Erythroderma, Sezary

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Mycosis Fungoides
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
3.	Graft vs Host Disease (Graft-Versus-Host Disease)
4.	Autoimmune Diseases (Autoimmune Disease)
5.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)

Experts

1.	Rook, Alain H: 3 articles (05/2008 - 05/2007)
2.	Wysocka, Maria: 2 articles (09/2007 - 05/2007)
3.	Benoit, Bernice M: 2 articles (09/2007 - 05/2007)
4.	Newton, Sarah B: 2 articles (09/2007 - 05/2007)
5.	Yoon, Jessica S: 2 articles (09/2007 - 05/2007)
6.	Shane, Ryan: 1 article (05/2008)
7.	Kerl, Katrin: 1 article (05/2008)
8.	French, Lars E: 1 article (05/2008)
9.	Contassot, Emmanuel: 1 article (05/2008)
10.	Dupuis, Marc: 1 article (05/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Sezary Syndrome:

1.	vorinostat (suberoylanilide hydroxamic acid)FDA Link 09/01/2007 - "In two phase II trials, Vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 30-31% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome. " Order ALL the reference details at left...
2.	Cladribine FDA LinkGeneric 02/15/1997 - "2-Chlorodeoxyadenosine treatment in the Sezary syndrome." 02/01/1996 - "We investigated the efficacy of 2-chlorodeoxyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS). " Order ALL the reference details at left...
3.	Immunoglobulins (Immunoglobulin)IBA 01/01/1984 - "Regulatory activity of neoplastic T cells in Sezary syndrome on in vitro immunoglobulin production." 03/12/1980 - "[Sezary syndrome with serum monoclonal immunoglobulin. " 03/12/1980 - "In a case of Sezary syndrome with monoclonal serum immunoglobulin (IgM kappa) haematological investigations and a study of lymphocyte membrane markers failed to demonstrate any proliferation of B-lymphocytes. " 03/12/1980 - "In order to test the hypothesis that the T-cells of Sezary syndrome and the B-cells producing the monoclonal immunoglobulin derived from the same stem cells and belonged to the same clone, an antiserum specific for the idiotype determinants of the IgM was used to detect by membrane immunofluorescence the possible presence in Sezary cells of surface receptors containing these determinants. " 01/01/1975 - "In addition, in control studies no such suppression of immunoglobulin synthesis was seen when normal cells were co-cultured with lymphocytes from unrelated normals, patients with isolated IgA deficiency, patients with chronic lymphocytic leukemia or patients with the Sezary syndrome, a T cell leukemia nor were they inhibited when incubated with T cells from unrelated normals. " Order ALL the reference details at left...
4.	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/01/2003 - "The aim of the study was to evaluate the usefulness of the T-cell receptor (TCR) gamma gene rearrangement analysis in the diagnosis of mycosis fungoides (MF) and Sezary syndrome (SS). " 07/01/1994 - "Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE)." 06/15/1992 - "We investigated the correlation between the detection of clonal rearrangement of the T-cell antigen receptor gene (TCRR) in lymph node tissue with histopathologic lymph node classification in 33 patients with mycosis fungoides with and without the Sezary Syndrome. " 08/01/2006 - "We have examined in detail the features of the T-cell receptor beta (TCRB) gene rearrangements in 20 individuals with well-defined stages of cutaneous T-cell lymphoma (CTCL) comprising 10 cases with early-stage mycosis fungoides (MF) and 10 cases with late-stage MF or Sezary syndrome. " 07/01/1994 - "We used a gene amplification strategy to analyze T-cell receptor (TCR) gene rearrangements in 185 specimens, including mycosis fungoides/Sezary syndrome (MF/SS), other cutaneous neoplasms, inflammatory dermatoses, reactive lymphoid tissues, and normal skin. " Order ALL the reference details at left...
5.	Interleukin-2 (IL2)IBA 09/15/1994 - "Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study." 05/01/2001 - "Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells." 08/20/1996 - "Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome." 01/01/1981 - "By using purified TCGF free of PHA and of lymphokines other than TCGF, we have recently been able to grow routinely neoplastic T cells from patients with leukemias and lymphomas of mature T cells, e.g., from patients with the Sezary syndrome and those with mycosis fungoides (cutaneous T-cell leukemias and lymphomas). " 01/01/2001 - "Chromosomally clonal T cells in the skin, blood, or lymph nodes of two Sezary syndrome patients express CD45RA, CD45RO, CDw150, and interleukin-4, but no interleukin-2 or interferon-gamma." Order ALL the reference details at left...
6.	Interleukin-2 Receptor alpha SubunitIBA 05/01/2001 - "Here, we study the regulation of IL-2Ralpha expression and STATs in a tumor cell line obtained from peripheral blood from a patient with Sezary syndrome (SS), a leukemic variant of CTCL. " Order ALL the reference details at left...
7.	NeopterinIBA 01/01/2004 - "RESULTS: The study revealed that neopterin, beta2-MG and sIL-2R are significantly elevated in Sezary syndrome, whereby sIL-2R seemed to be the most sensitive marker and is typically increased in Sezary syndrome. " Order ALL the reference details at left...
8.	Immunoglobulin M (IgM)IBA 03/12/1980 - "In a case of Sezary syndrome with monoclonal serum immunoglobulin (IgM kappa) haematological investigations and a study of lymphocyte membrane markers failed to demonstrate any proliferation of B-lymphocytes. " 03/12/1980 - "In order to test the hypothesis that the T-cells of Sezary syndrome and the B-cells producing the monoclonal immunoglobulin derived from the same stem cells and belonged to the same clone, an antiserum specific for the idiotype determinants of the IgM was used to detect by membrane immunofluorescence the possible presence in Sezary cells of surface receptors containing these determinants. " Order ALL the reference details at left...
9.	Carbon MonoxideIBA 01/01/1975 - "In addition, in control studies no such suppression of immunoglobulin synthesis was seen when normal cells were co-cultured with lymphocytes from unrelated normals, patients with isolated IgA deficiency, patients with chronic lymphocytic leukemia or patients with the Sezary syndrome, a T cell leukemia nor were they inhibited when incubated with T cells from unrelated normals. " Order ALL the reference details at left...
10.	alemtuzumab (Campath)FDA Link 06/01/2003 - "Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome." Order ALL the reference details at left...

Therapies and Procedures

1.	Photopheresis 01/01/2002 - "Over the last decade, extracorporeal photopheresis has been the only single treatment that has been shown to improve survival in patients with Sezary syndrome, although its true efficacy and place in combination therapy remain unclear. " 09/01/1999 - "Furthermore, a 20%-25% complete response rate with photopheresis alone, or in combination with other biologic response modifiers, has been obtained at our institution among patients with Sezary syndrome. " 01/01/1997 - "BACKGROUND: In patients with Sezary syndrome undergoing extracorporeal photochemotherapy it is currently thought that photodamage of a congruent number of pathogenic circulating T cells is a necessary condition for a specific anticlonal response to be induced against these cells by the immune system. " 08/01/1996 - "Peripheral blood T-cell subpopulations of Sezary syndrome patients, including the malignant clone, were equally susceptible to apoptosis subsequent to either photopheresis or PUVA treatment. " 08/01/1996 - "In this study, we investigated the ability of extracorporeal photopheresis (ExP) and in vitro PUVA (8-methoxy-psoralen + ultraviolet A) therapy to induce apoptosis in peripheral blood mononuclear cells from Sezary syndrome patients and normal controls. " Order ALL the reference details at left...
2.	Transplants (Transplant) 02/01/2009 - "Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion." 08/01/2003 - "Extracorporeal photochemotherapy (ECP) has been shown to be effective in variety of pathologic diseases such as Sezary syndrome, autoimmune diseases, organ graft rejection and graft versus host disease. " Order ALL the reference details at left...
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/01/1999 - "Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor." 01/01/1999 - "Bone marrow transplantation (BMT) from a matched unrelated donor was performed in a 22-year-old woman with a 10-year history of Sezary syndrome who had failed treatment with corticosteroids, methotrexate, photochemotherapy, photopheresis, hydroxyurea, interferon-alpha, and cladarabine. " Order ALL the reference details at left...
4.	PUVA Therapy 08/01/1996 - "In this study, we investigated the ability of extracorporeal photopheresis (ExP) and in vitro PUVA (8-methoxy-psoralen + ultraviolet A) therapy to induce apoptosis in peripheral blood mononuclear cells from Sezary syndrome patients and normal controls. " Order ALL the reference details at left...
5.	Immunotherapy 05/01/2001 - "Consequently, the expression of SC5 receptor in the peripheral blood of Sezary syndrome patients may serve not only to detect the presence of circulating malignant CD4+ cells but also as a target for immunotherapy." 11/01/2007 - "Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Sezary Syndrome

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 6 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>